Kathryn Guarini, a director at Regeneron Pharmaceuticals, Inc., has disclosed multiple stock transactions in a recent filing. This activity is significant as it reflects her continued involvement and confidence in the company's future. The transactions were reported on November 3, 2026, and pertain to actions taken on October 30, 2026.

Background

Regeneron Pharmaceuticals, Inc. is a prominent player in the pharmaceutical industry, specifically categorized under Pharmaceutical Preparations. The company is based in Tarrytown, New York, and is known for its innovative approaches to drug development and biotechnology. Regeneron trades under the ticker symbol REGN on the stock exchange.

What the Filing Says

According to the filing, Guarini acquired 400 shares of Regeneron common stock at a price of $719.37 per share. Additionally, she disposed of 400 shares at a price of $900.00 per share. After these transactions, she holds a total of 603 shares of the company. The filing noted that these transactions were made pursuant to a plan intended to comply with Rule 10b5-1(c), adopted on February 13, 2026.

Impact

Guarini's transactions may influence investor sentiment regarding Regeneron Pharmaceuticals. As a director, her buying and selling of stock can be seen as a signal of confidence in the company's prospects. This activity also highlights the ongoing engagement of insiders within the pharmaceutical sector, which is often scrutinized by investors looking for indicators of future performance.

What's Next

The filing does not say what happens next.